Company Overview
| Stock Name | GBG Holdings |
|---|---|
| Stock Code | 08372 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 成熟醫療儀器分銷商,於香港醫療儀器市場擁有逾19年經驗,提供一站式醫療儀器解決方案,包括市場趨勢分析、醫療儀器採購、售後服務、技術支援及培訓服務、醫療儀器租賃服務及質量保證。產品分為醫療耗材、醫療設備、醫療器械及其他醫療保健產品,客戶主要包括香港公立及私立醫院、私家診所、非牟利組織、大學及個別客戶。 |
| Listing Date | 2018-03-29 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港新界荃灣沙咀道6號嘉達環球中心29樓2901-2903室及2905室 |
| Business Address (Hong Kong) | 香港新界荃灣沙咀道6號嘉達環球中心29樓2901-2903室及2905室 |
| Place of Incorporation | 開曼群島 |
| Listing Method | 發售以供認購 + 發售以供配售 |
| Listing Board | GEM |
| Website | www.grandbrilliancegroup.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 0.34 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2018-03-19 to 2018-03-22 |
| Global Offering Shares | 168,000,000 shares |
| HK Public Offer Shares (Initial) | 16,800,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 151,200,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 800,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 56,280,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 122.6M |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +7561% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 268,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約11.8百萬港元 |
| Period-End Cash Balance | 約9.8百萬港元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 約14.1百萬港元 |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2016-03 | 2017-03 | 2017-10 |
|---|---|---|---|
| Revenue | 52,876 | 51,657 | 30,958 |
| Cost of sales | -24,688 | -25,631 | -14,752 |
| Gross profit | 28,188 | 26,026 | 16,206 |
| Other income and gains, net | 116 | 74 | 50 |
| Selling and distribution expenses | -800 | -795 | -437 |
| Administrative expenses | -12,311 | -11,277 | -6,569 |
| Net finance costs | -7 | 0 | 0 |
| Profit before tax | 15,530 | 14,190 | 2,024 |
| Income tax expense | -2,551 | -2,388 | -1,645 |
| Profit for the year | 12,979 | 11,802 | 379 |
Balance Sheet
| Item | 2016-03 | 2017-03 | 2017-10 |
|---|---|---|---|
| Cash and cash equivalents | 16,922 | 9,776 | 8,894 |
| Trade and bills receivables | 7,541 | 7,689 | 12,963 |
| Inventories | 14,706 | 13,718 | 13,957 |
| Total current assets | 40,191 | 31,371 | 35,814 |
| Total current liabilities | 12,614 | 4,086 | 9,012 |
| Total equity | 31,665 | 31,232 | 31,683 |
Cash Flow Statement
| Item | 2016-03 | 2017-03 | 2017-10 |
|---|---|---|---|
| Net cash from operating activities | 15,908 | 4,747 | -3,886 |
| Net cash from investing activities | -3,901 | -11,646 | -4,078 |
| Net cash from financing activities | 240 | -247 | 4,052 |
| Net increase in cash | 12,247 | -7,146 | -3,912 |
| Depreciation of PP&E | 482 | 453 | 160 |
| Purchase of PP&E | -113 | -43 | -1,343 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.4 |
|---|---|
| First Day Open | HK$ 0.415 |
| First Day Change | 19.40% |
| First Day Volume | 258040000.0 |
| First Day Turnover | 98842200.0 |
| Use of Proceeds | 1、約6.9百萬港元(或約20.0%)將用于追加投資,拓展服務組合及加強銷售及營銷活動,以進一步滲透醫療儀器市場及提高我們在香港醫療儀器市場的市場份額;
2、約10.7百萬港元(或約30.9%)將用于招聘兩名工程師、一名登記護士、一名物理治療師、七名產品代表、兩名營銷人員、兩名研發人員、兩名信息科技技術人員、一名倉管員、一名行政人員、一名會計人員、兩名司機及兩名物流人員,擴大勞工隊伍及支付彼等直至2020年3月31日前的薪金,以應對我們業務的擴張;
3、約8.8百萬港元(或約25.4%)將部分用于近期選擇性尋求戰略收購機會;
4、約1.3百萬港元(或約3.8%)將用于加大研發及產品開發力度;
5、約2.5百萬港元(或約7.1%)將用于升級我們的資訊科技系統;
6、約2.2百萬港元(或約6.4%)將用于擴大我們的倉庫、建立展廳及升級辦公室的功能;
7、約2.2百萬港元(或約5.5%)將用作本集團的一般營運資金。 |
Underwriting Syndicate
Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券(香港)有限公司 CE ABY236
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 黃碧君 | — |
| Company Secretary | 陳震昇 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 黃女士及B&A Success(黃女士全資擁有)上市後持股69.68%,為控股股東;Infinite Crystal持股5.06%,由趙先生擁有61.11%權益及原先生等透過Sunstrike Investments Limited擁有38.89%權益;苗醫生為黃女士配偶,享有配偶權益。 |
|---|




